Vol. 45 (3): 449-458, May – June, 2019

doi: 10.1590/S1677-5538.IBJU.2018.0798


Andre Deeke Sasse 1, Rodolfo Borges dos Reis 2, Lucas Mendes Nogueira 3, Fernando Cotait Maluf 4, Daniel Herchenhorn 5, Oren Smaletz 6, Volney Soares Lima 7, Fábio Schutz 4, Diogo Bastos 8, Evanius Garcia Wiermann 9, Igor Alexandre Protzner Morbeck 10, Leonardo Fontes Jardim 8, Vinicius Carrera Souza 9, Icaro Thiago Carvalho 6, Elton Trigo Teixeira Leite 11, Archimedes Nardozza Jr. 12, Antonio Carlos Lima Pompeo 13, Francisco Bretas 14, Marcos Lima de Oliveira Leal 15, Marcus Vinicius Sadi 12, José Ricardo Tuma da Ponte 16, Gustavo F. Carvalhal 17
1 Grupo SONHE, Oncologia, Campinas, SP, Brasil; 2 Departamento de Urologia, Universidade de São Paulo- USP, Campus de Ribeirão Preto, Ribeirão Preto, SP, Brasil; 3 Divisão de Urologia e Departamento de Cirurgia Hospital das Clínicas, Universidade Federal de MG – UFMG, Belo Horizonte, MG, Brasil; 4 Hospital Benefi cência Portuguesa de São Paulo, SP, Brasil; 5 Rede D’Or São Luiz, Rio de Janeiro, Brasil; 6 Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brasil; 7 Oncocentro, Belo Horizonte, MG, Brasil; 8 Departamento de Oncologia, Instituto do Câncer do Estado de São Paulo – ICESP, SP, Brasil; 9 Sociedade Brasileira de Oncologia Clinica – SBOC, Belo Horizonte, MG, Brasil; 10 Clinica AMO, Salvador, Bahia, Brasil; 11 Hospital Sírio-Libanês, São Paulo, SP, Brasil; 12 Departamento de Urologia e Cirurgia, Universidade Federal de São Paulo – UNIFESP, São Paulo, SP, Brasil; 13 Faculdade de Medicina do ABC, Urologia, Santo André, SP, Brasil; 14 Hospital Mater Dei, Belo Horizonte, MG, Brasil; 15 Departamento de Urologia, Universidade Federal da Bahia – UFBA, Salvador, Bahia, Brasil; 16 Departamento de Urologia, Universidade do Estado do Pará – UEPA, Belém, PA, Brasil; 17 Divisão de Urologia e Departamento de Cirurgia, Pontifícia Universidade Católica do Rio Grande do Sul – PUC RS, Porto Alegre, RS, Brasil

Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers.
The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The first Brazilian Con-sensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of different technologies is a big challenge, especially in the Sistema Único de Saúde (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer.
This Consensus was written through a joint initiative of the Brazilian Society of Clinical Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.

Keywords: Prostatic Neoplasms; Therapeutics; Consensus

[Full Text]